View Our
Publications
DetermaCNI Publications
Klinsing S, Beck J, Weber K, et al. (2024). Detection of diagnostic somatic copy number alterations from cerebrospinal fluid cell-free DNA in brain tumor patients. Acta Neuorpathologica Communications. 12:177. – View Article
Schirmer M, Beck J, Leu M, et al. (2018). Cell-Free Plasma DNA for Disease Stratification and Prognosis in Head and Neck Cancer. Clin Chem 64(6):959-970. – View Article
Schütz E, Akbari MR, Beck J, et al. (2015). Chromosomal instability in cell-free DNA is a serum biomarker for prostate cancer. Clin Chem 61(1):239-248. – View Article
Weiss G, Beck J, Braun D, et al. (2017). Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy. Clin Cancer Res 23(17):5074-5081. – View Article
Weiss G, Blaydorn L, Beck J, et al. (2018). Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. Invest New Drugs 36(1):96-102. – View Article
DetermaIO Publications
Dugo M, Huang C, Egle D, et al. (2024). The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer. Clinical Cancer Research. 30 (21): 4900–4909. – View Article
Antoniotti C, Boccaccino A, Seitz R, et al. (2023). An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer. Clin Cancer Res CCR-22-3878. – View Article
Iwase T, Blenman K, Li X, et al. (2021). A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer. Cancers 13(19):4839. – View Article
Nielsen T, Ring B, Seitz R, et al. (2021). A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies. Heliyon 7(3):e06438. – View Article
Nielsen T, Varga M, Cronister C, et al. (2023). The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort. Cancer immunology, immunotherapy: CII, 10.1007/s00262-023-03401-x. – View Article
Page D, Pucilowska J, Chun B, et al. (2023). A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer. NPJ Breast Cancer 9(1):53. – View Article
Ranganath H, Jain A, Smith J, et al. (2022). Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer. BMC cancer 22:407. – View Article
Saltman D, Nielsen T, Salina D, et al. (2021). Characterization of the tumor immune-microenvironment of adenocarcinoma of lung with a metastatic lesion in the pancreas treated successfully with first-line, single-agent pembrolizumab. Ther Adv Med Oncol 13:17588359211010156. – View Article
Saltman D, Varga M, Nielsen T, et al. (2023). 27-gene Immuno-Oncology (IO) Score is Associated With Efficacy of Checkpoint Immunotherapy in Advanced NSCLC: A Retrospective BC Cancer Study. Clin Lung Cancer 24(2):137-144. – View Article
Seitz R, Hurwitz M, Nielson T, et al. (2022). Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients. J Transl Med 20:370. – View Article
Spring L, Bar Y, Isakoff S. (2022). The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer. J Natl Compr Canc Netw 20(6):723-734. – View Article
VitaGraft Publications
Mayer KA, Schrezenmeier E , Diebold M, et al. (2024). A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection. NEJM doi:10.1056/NEJMoa2400763. – View Article
Osmanodja B, Akifova A, Budde K, et al. (2024). Donor-Derived Cell-Free DNA as a Companion Biomarker for AMR Treatment With Daratumumab: Case Series. Transplant International doi:10.3389/ti.2024.13213 – View Article
Akifova A, Budde K, Oellerich M, et al. (2024). Perspective for Donor-Derived Cell-Free DNA in Antibody-Mediated Rejection After Kidney Transplantation: Defining Context of Use and Clinical Implications. Transplant International doi:10.3389/ti.2024.13239 – View Article
Akifova A, Budde K, Choi M, et al. (2023). Donor-Derived Cell-Free DNA in Biopsy-Proven Antibody-Mediated Rejection Versus Recurrent IgA Nephropathy After Kidney Transplantation. Kidney International Reports doi:10.1016/j.ekir.2023.07.011 – View Article
Baumann AK, Beck J, Kirchner T, et al. (2022). Elevated Fractional Donor-Derived Cell-Free DNA During Subclinical Graft Injury After Liver Transplantation. Liver Transpl 28(12):1911-1919. – View Article
Beck J, Bierau S, Balzer S, et al. (2013). Digital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury. Clin Chem 59(12):1732-41. – View Article
Beck J, Oellerich M, Schulz U, et al. (2015). Donor-Derived Cell-Free DNA Is a Novel Universal Biomarker for Allograft Rejection in Solid Organ Transplantation. Transplant Proc 47(8):2400-3. – View Article
Beck J, Oellerich M, Schütz E. (2018). A Universal Droplet Digital PCR Approach for Monitoring of Graft Health After Transplantation Using a Preselected SNP Set. Methods Mol Biol 1768:335-48. – View Article
Kanzaw P, Kollmar O, Schütz E, et al. (2014). Graft-derived cell-free DNA as an early organ integrity biomarker after transplantation of a marginal HELLP syndrome donor liver. Transplantation 98(5):e43-5. – View Article
Knüttgen F, Beck J, Dittrich M, et al. (2022). Graft-derived Cell-free DNA as a Noninvasive Biomarker of Cardiac Allograft Rejection: A Cohort Study on Clinical Validity and Confounding Factors. Transplantation 106(3):615-622. – View Article
Oellerich M, Beck J, Kanzaw P, et al. (2016). Graft-derived cell-free DNA as a marker of graft integrity after transplantation. Ther Drug Monit 38:153-76. – View Article
Oellerich M, Schütz E, Kanzow P, et al. (2014). Use of graft-derived cell-free DNA as an organ integrity biomarker to reexamine effective tacrolimus trough concentrations after liver transplantation. Ther Drug Monit 36(2):136-40. – View Article
Oellerich M, Sherwood K, Keown P, et al. (2021). Liquid biopsies: donor-derived cell-free DNA for the detection of kidney allograft injury. Nat Rev Nephrol 17(9):591-603. – View Article
Oellerich M, Shipkova M, Asendorf T, et al. (2019) Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: Results from a prospective observational study. Am J Transplant 19(11):3087-99. – View Article
Osmanodja B, Akifova A, Budde K, et al. (2021). Absolute or Relative Quantification of Donor-derived Cell-free DNA in Kidney Transplant Recipients: Case Series. Transplant Direct 7(11):e778. – View Article
Schütz E, Asendorf T, Beck J, et al. (2020) Time-dependent apparent increase in dd-cfDNA percentage in clinically stable patients between one and five years following kidney transplantation. Clin Chem 66(10):1290-99. – View Article
Schütz E, Fischer A, Beck J, et al. (2017). Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: A prospective, observational, multicenter cohort study. PLoS Med 14(4):e1002286. – View Article
